News
LB Pharma needed $350 million to advance a promising schizophrenia candidate at a time when the biotech markets were locked up tight. Fortunately, it wasnât CEO Heather Turnerâs first rodeo.
FEATURED STORIES
Corsera Healthâs Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotechâs mission and vision for the next generation of cardiovascular care.
Billions of dollarsâ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste. A data-driven approach offers a practical path to greater efficiency.
Sales of Merckâs longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Following the FDAâs refusal to review Modernaâs investigational mRNA flu vaccine last week, Commissioner Marty Makary faced questions from the U.S. president about the agencyâs handling of vaccines. Itâs a clear signal that the tension long brewing at the drug regulator has now gone all the way to the top.
THE LATEST
Seven biotech unicorns are advancing AI-powered drug discovery and developmentâbut must contend with a difficult investing environment where competition is steep and the usual roads to exit are uncertain.
In this bonus episode, BioSpaceâs Vice President of Marketing â Chantal Dresnerâ and Careers Editor â Angela Gabrielâ take a look at Q2 job market performance, layoffs and wider employment trends and policies impacting the biopharma workforce.
Thousands of employees across HHS were terminated Monday evening after the U.S. Supreme Court ruled last week that the Trump administration could move forward with its sweeping reorganization of the agency.
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the heels of the landmark Yeztugo approval.
According to Makary, reducing user feesâwhich make up just under half of the FDAâs budgetâcould make it easier for smaller companies, individual investors and academics to participate in the process.
The molecule, developed in collaboration with Massachusetts-based Kailera Therapeutics, is headed for a new drug application in China and global clinical trials.
More than thirty years since its 1993 founding, Catherine Owen Adams and Elizabeth Thompsonâthe R&D combo that has led Acadia since last yearâare managing two products on the market and a pipeline estimated to be worth an additional $12 billion in sales.
Despite the FDA commissionerâs promises of partnership and collaboration, personnel changes and continued federal cuts create uncertainty for an industry already struggling with nearly half a decade of investment scarcity.
The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its cardiovascular and kidney disease pipelines.
Takedaâs oveporexton improved wakefulness, attention and other key narcolepsy endpoints âwith a high degree of statistical significance,â according to Jefferies analysts.